PMID- 29877321
OWN - NLM
STAT- MEDLINE
DCOM- 20181029
LR  - 20231004
IS  - 1745-7254 (Electronic)
IS  - 1671-4083 (Print)
IS  - 1671-4083 (Linking)
VI  - 39
IP  - 7
DP  - 2018 Jul
TI  - Leptin, cardiovascular diseases and type 2 diabetes mellitus.
PG  - 1176-1188
LID - 10.1038/aps.2018.40 [doi]
AB  - Leptin, an adipokine that is implicated in the control of food intake via 
      appetite suppression, may also stimulate oxidative stress, inflammation, 
      thrombosis, arterial stiffness, angiogenesis and atherogenesis. These 
      leptin-induced effects may predispose to the development of cardiovascular 
      diseases. In the present review we discuss the evidence linking leptin levels 
      with the presence, severity and/or prognosis of both coronary artery disease and 
      non-cardiac vascular diseases such as stroke, carotid artery disease, peripheral 
      artery disease (PAD) and abdominal aortic aneurysms (AAA) as well as with chronic 
      kidney disease (CKD) and type 2 diabetes mellitus (T2DM). Leptin levels have been 
      positively associated with the presence, severity, extent and lesion complexity 
      of coronary atherosclerosis as well as with the presence, severity and poor 
      clinical outcomes of both ischemic and hemorrhagic strokes. But conflicting 
      results also exist. Furthermore, leptin was reported to independently predict 
      common carotid intima-media thickness and carotid plaque instability. A link 
      between hyperleptinemia and PAD has been reported, whereas limited data were 
      available on the potential association between leptin and AAA. Elevated leptin 
      concentrations have also been related to CKD incidence and progression as well as 
      with insulin resistance, T2DM, micro- and macrovascular diabetic complications. 
      Statins and antidiabetic drugs (including sitagliptin, metformin, pioglitazone, 
      liraglutide and empagliflozin) may affect leptin levels. Further research is 
      needed to establish the potential use (if any) of leptin as a therapeutic target 
      in these diseases.
FAU - Katsiki, Niki
AU  - Katsiki N
AD  - Second Propedeutic Department of Internal Medicine, Medical School, Aristotle 
      University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
FAU - Mikhailidis, Dimitri P
AU  - Mikhailidis DP
AD  - Department of Clinical Biochemistry, Royal Free Hospital Campus, University 
      College London Medical School, University College London (UCL), London, UK. 
      MIKHAILIDIS@aol.com.
FAU - Banach, Maciej
AU  - Banach M
AD  - Department of Hypertension, Medical University of Lodz, Lodz, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180607
PL  - United States
TA  - Acta Pharmacol Sin
JT  - Acta pharmacologica Sinica
JID - 100956087
RN  - 0 (Biomarkers)
RN  - 0 (Leptin)
SB  - IM
MH  - Biomarkers/blood
MH  - Cardiovascular Diseases/*blood/drug therapy
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy
MH  - Humans
MH  - Leptin/*blood
PMC - PMC6289384
OTO - NOTNLM
OT  - abdominal aortic aneurysms
OT  - carotid artery disease
OT  - chronic kidney disease
OT  - coronary heart disease
OT  - leptin
OT  - obesity
OT  - peripheral artery disease
OT  - stroke
EDAT- 2018/06/08 06:00
MHDA- 2018/10/30 06:00
PMCR- 2019/07/01
CRDT- 2018/06/08 06:00
PHST- 2018/02/18 00:00 [received]
PHST- 2018/05/02 00:00 [accepted]
PHST- 2018/06/08 06:00 [pubmed]
PHST- 2018/10/30 06:00 [medline]
PHST- 2018/06/08 06:00 [entrez]
PHST- 2019/07/01 00:00 [pmc-release]
AID - 10.1038/aps.2018.40 [pii]
AID - 106 [pii]
AID - 10.1038/aps.2018.40 [doi]
PST - ppublish
SO  - Acta Pharmacol Sin. 2018 Jul;39(7):1176-1188. doi: 10.1038/aps.2018.40. Epub 2018 
      Jun 7.